MYELOID-TARGETED TLR9 IMMUNOTHERAPY

Reprogramming the tumor microenvironment in solid tumors.

Arcamyra is a clinical-stage immuno-oncology company advancing ACM-CpG, a polymersome-encapsulated TLR9 agonist designed to improve the exposure and cellular delivery of CpG following systemic or local administration.

The science View pipeline

5/6*

patients with stable disease (RECIST), Phase 1

* for DL2 & DL3 patients

dose-limiting toxicities in Phase 1

10,500

eligible US peritoneal carcinomatosis patients / year

2029

FDA Accelerated Approval target

THE OPPORTUNITY

Delivery, not TLR9 biology, has been the limiting factor.

Clinical development of earlier TLR9 agonists has been limited by several factors, including rapid systemic clearance, restricted exposure to relevant immune-cell populations, route-of-administration constraints, and heterogeneous activity across tumor types.

THE ACM POLYMERSOME PLATFORM

A polymersome engineered to deliver the agonist to myeloid antigen-presenting cells.

Our polymersome encapsulation is designed to promote preferential uptake by myeloid antigen-presenting cells, modifying the pharmacological profile and downstream immune response of the TLR9 agonist.

—>24-hour depot effect at the injection site

—Preferential uptake by myeloid antigen-presenting cells

—Multiple routes: intramuscular, intraperitoneal, intratumoral

ACM-CpG is preferentially taken up by macrophages and dendritic cells, activating endosomal TLR9 within pDCs and macrophages; pDCs produce IFN-alpha and macrophages repolarize, driving CD8 T-cell recruitment into an immune-infiltrated tumor microenvironment.

MECHANISM OF ACTION

Designed to promote immune-cell activation and infiltration.

CLINICAL VALIDATION IN HUMANS

5/6*

patients with stable disease by RECIST in the Phase 1 dose-escalation study — all single-agent, intramuscular.

* for DL2 & DL3 patients.

Investigator-initiated Phase 1, NCCS Singapore (NCT06587295). n=9 treated; data cut-off March 2026.

—{{ c }}

Pipeline

PROGRAMINDICATIONROUTE / MODALITY PRECLINICAL PHASE I PHASE II

Lead program (peritoneal carcinomatosis): FDA IND cleared, trial initiated (NCT07658196). Solid / metastatic tumours with a focus on the NSCLC subgroup: investigator-initiated trial ongoing at NCCS Singapore (NCT06587295).

LEAD PROGRAM

Peritoneal carcinomatosis — an indication with no approved alternatives.

Intraperitoneal ACM-CpG produced complete tumor resolution and durable immune memory in the MC38 model. Current standard of care (HIPEC) is highly toxic with limited eligibility.

MARKET OPPORTUNITY